A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Latest Information Update: 03 Apr 2026
At a glance
- Drugs EYE 201 (Primary) ; Aflibercept
- Indications Macular degeneration; Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
Most Recent Events
- 01 Apr 2026 New trial record